Novel therapeutic strategies targeting HIV integrase

Peter K. Quashie, Richard D. Sloan, Mark A. Wainberg*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract / Description of output

Integration of the viral genome into host cell chromatin is a pivotal and unique step in the replication cycle of retroviruses, including HIV. Inhibiting HIV replication by specifically blocking the viral integrase enzyme that mediates this step is an obvious and attractive therapeutic strategy. After concerted efforts, the first viable integrase inhibitors were developed in the early 2000s, ultimately leading to the clinical licensure of the first integrase strand transfer inhibitor, raltegravir. Similarly structured compounds and derivative second generation integrase strand transfer inhibitors, such as elvitegravir and dolutegravir, are now in various stages of clinical development. Furthermore, other mechanisms aimed at the inhibition of viral integration are being explored in numerous preclinical studies, which include inhibition of 3' processing and chromatin targeting. The development of new clinically useful compounds will be aided by the characterization of the retroviral intasome crystal structure. This review considers the history of the clinical development of HIV integrase inhibitors, the development of antiviral drug resistance and the need for new antiviral compounds.

Original languageEnglish
Article number34
JournalBMC Medicine
Publication statusPublished - 12 Apr 2012

Keywords / Materials (for Non-textual outputs)

  • Crystal structure
  • Dolutegravir
  • HIV integrase
  • Mutations
  • New drugs
  • Raltegravir
  • Resistance


Dive into the research topics of 'Novel therapeutic strategies targeting HIV integrase'. Together they form a unique fingerprint.

Cite this